Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789925 | 0.88 | HDAC2 (0.51) | AAK1HDAC1HDAC2HDAC3MAP4K4 | |
| SCHEMBL15160030 | 0.87 | GAA (0.52) | AAK1RXFP1MAP4K4GAAMAPT | |
| SCHEMBL29741562 | 0.87 | HPGD (0.49) | AAK1HDAC1HDAC2HDAC3 | |
| SCHEMBL3407965 | 0.87 | HPGD (0.49) | AAK1HDAC1HDAC2HDAC3 | |
| SCHEMBL13606210 | 0.86 | HDAC1 (0.43) | HDAC1RXFP1MAP4K4GAANR1H2 | |
| SCHEMBL20057682 | 0.86 | AAK1 (0.47) | AAK1HDAC1HDAC2HDAC3RXFP1 | |
| SCHEMBL19935638 | 0.86 | KCNQ4 (0.40) | AAK1RXFP1MAP4K4GAAMAPT | |
| SCHEMBL14691487 | 0.86 | LMNA (0.43) | AAK1RXFP1MAP4K4MAPTMAPK1 | |
| SCHEMBL7955810 | 0.84 | AAK1 (0.45) | AAK1HDAC1HDAC2HDAC3GAA | |
| SCHEMBL3791592 | 0.84 | HDAC2 (0.51) | AAK1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981780-B2 | Polymeric gel and preparation method therefor, and article comprising same | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-05-14 | — | — | US | disclosed |
| WO-2022177151-A1 | NITRIC OXIDE-SENSITIVE HYDROGEL | 포항공과대학교 산학협력단 | 2022-08-25 | — | — | WO | disclosed |
| US-11384204-B2 | Varnish for photo alignment film and liquid crystal display device | JAPAN DISPLAY INC. (JP) | 2022-07-12 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| CN-108047142-B | Heteroaryl compounds and uses thereof | 西建卡尔有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20210155755-A1 | VARNISH FOR PHOTO ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | JAPAN DISPLAY INC. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10968392-B2 | Liquid crystal aligning agent for photoalignment, liquid crystal alignment film and liquid crystal display device using it, and diamine and polymer | JNC CORPORATION (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10947345-B2 | Varnish for photo alignment film and liquid crystal display device | JAPAN DISPLAY INC. (JP) | 2021-03-16 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8338439-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2519235-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2361248-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | AAK1 4713/4885HDAC1 2071/4885HDAC2 1013/4885 |
| US-10968392-B2 | Liquid crystal aligning agent for photoalignment, liquid crystal alignment film and liquid crystal display device using it, and diamine and polymer | DDT, DCLRE1A, DVL1 | AAK1 190/4885HDAC1 4780/4885HDAC2 4781/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | AAK1 4713/4885HDAC1 2071/4885HDAC2 1013/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | AAK1 210/4885HDAC1 1653/4885HDAC2 1206/4885 |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | AAK1 4713/4885HDAC1 2071/4885HDAC2 1013/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | AAK1 4713/4885HDAC1 2071/4885HDAC2 1013/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | AAK1 254/4885HDAC1 1215/4885HDAC2 975/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | AAK1 4713/4885HDAC1 2071/4885HDAC2 1013/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | AAK1 210/4885HDAC1 1653/4885HDAC2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.